Scarica l'app Stockscreener
14.18
0.70%
-0.10
Precedente Chiudi:
$14.28
Aprire:
$14.23
Volume 24 ore:
1.87M
Relative Volume:
0.65
Capitalizzazione di mercato:
$44.80B
Reddito:
$29.63B
Utile/perdita netta:
$260.53M
Rapporto P/E:
179.95
EPS:
0.0788
Flusso di cassa netto:
$5.51B
1 W Prestazione:
-1.66%
1M Prestazione:
+4.34%
6M Prestazione:
-5.40%
1 anno Prestazione:
+2.75%
Intervallo 1D:
$14.16
$14.33
Intervallo di 1 settimana:
$14.16
$14.54
Portata 52W:
$12.80
$15.69
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Confronta TAK con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
14.18 | 45.11B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
ZTS
Zoetis Inc
|
118.65 | 53.06B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
9.52 | 42.44B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.46 | 32.59B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
489.31 | 20.84B | 3.08B | 1.24B | 1.07B | 25.61 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-07-19 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-10-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Iniziato | Cowen | Market Perform |
| 2019-08-15 | Downgrade | Daiwa Securities | Outperform → Neutral |
Mostra tutto
Takeda Pharmaceutical Co Adr Borsa (TAK) Ultime notizie
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net - AASTOCKS.com
Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA - GlobeNewswire Inc.
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Coca-Cola Upgraded, Boeing Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
ADR movements on the 11th: In yen terms, Kirin HD, Takeda Pharmaceutical, and Mitsui Metals showed gains. - 富途牛牛
Takeda Pharma ADR earnings beat by $278.84, revenue fell short of estimates - Investing.com Nigeria
CMBI Adds INNOVENT BIO (01801.HK) TP to $110.62 on Strategic Partnership with Takeda Pharmaceutical - AASTOCKS.com
BofAS Elevates INNOVENT BIO (01801.HK) TP to $113 as Co-op with Takeda Pharmaceutical Marks Major Step Towards Becoming Multinational Pharma Firm - AASTOCKS.com
CLSA Lifts INNOVENT BIO's TP to HKD120.1; Takeda Pharma Co-op Positive for Product Development - AASTOCKS.com
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors - Placera.se
INNOVENT BIO Opens Up 10% on Shr Issuance to Takeda Pharma at ~30% Premium w/ Licensing Deal Worth USD11.4B - AASTOCKS.com
INNOVENT BIO Issues Shrs at ~30% Premium to Takeda Pharma w/ Licensing Deal Involving USD11.4B - AASTOCKS.com
Bank of America Upgraded, Allstate Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
TAK vs. DSNKY: Which Stock Is the Better Value Option? - MSN
Walt Disney Upgraded, Southwest Airlines Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Takeda Pharmaceutical Company Limited (TAK) Stock Price, News, Quote & History - Yahoo
Pharma stocks in Asia fall as Trump announces 100% tariffs - Investing.com
5 Best High-Yield Dividend Stocks to Buy Now - The Motley Fool
Takeda’s narcolepsy drug shows positive results in phase 3 trials - Investing.com
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease - Placera.se
Japan's Takeda weighs India for global trials to speed up drug launches - MSN
Takeda Pharmaceutical ADR Earns RS Rating Upgrade - MSN
IBD Rating Upgrades: Warrior Met Coal Shows Improved Technical Strength - inkl
IBD Rating Upgrades: Takeda Pharmaceutical ADR Shows Improved Technical Strength - MSN
IBD Rating Upgrades: Genmab ADR Shows Improved Relative Price Strength - inkl
Waltham biotech’s latest pharma deal valued at $2B - The Business Journals
TAK’s Market Quandary: Decoding the Ups and Downs of 2025 - investchronicle.com
Blair William & Co. IL Cuts Stock Position in Takeda Pharmaceutical Co. (NYSE:TAK) - Defense World
VIS---In addition to collaborative drug discovery research with various partners, efforts to create a pipeline are being advanced. - 富途牛牛
Takeda Pharmaceutical Co Adr Azioni (TAK) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.10%
0.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):